榴莲视频app

You are here

Opioids

Program lead

Opioid prescribing in Australia has increased dramatically since the 1990s, with a larger array of opioid formulations with increased potency, particularly for chronic non-cancer pain. In parallel, there have been increases in diversion, extra-medical use and injection, opioid-related hospitalisation, opioid dependence and overdose. This program of work seeks to inform our understanding and responses to problematic opioid use, and improve the health of marginalised populations such as people who inject drugs and/or are opioid dependent.

Projects

Lead researchers

榴莲视频app of 榴莲视频app

External 

  • Louisa Degenhardt (榴莲视频app of NSW)
  • Jason Grebely (榴莲视频app of NSW)
  • Suzanne Nielsen (Monash 榴莲视频app)
  • Raimondo Bruno (榴莲视频app of Tasmania)
  • Paul Dietze (Burnet Institute)
  • Kari Lancaster (榴莲视频app of NSW)
  • Sarah Larney (榴莲视频app of Montreal)
  • Robert Ali (榴莲视频app of NSW)
  • Michael Farrell (榴莲视频app of NSW)

Lead institution
榴莲视频app of 榴莲视频app and 榴莲视频app of New South Wales

Project description

This project undertook a survey of 400 people who are opioid dependent across three jurisdictions (NSW, VIC and SA). The sample included people who are currently in treatment for opioid dependence and out of treatment populations (recruited through needle-syringe programs and other community organisations). We examined participants鈥� understanding of current treatment experiences, preferences, costs and impacts of current treatment policies. The primary aim of the survey was to examine perceptions of weekly or monthly injections of extended-release (depot) buprenorphine among people who used opioids regularly. Other studies are planned, including perceptions of other treatment options.

Outcomes

Funding

Industry grant (Indivior)

Researchers

榴莲视频app of 榴莲视频app

External collaborators

  • Michael Farrell (UNSW)
  • Louisa Degenhardt (榴莲视频app of NSW)
  • Marian Shanahan (榴莲视频app of NSW)
  • Jeyran Shahbazi (榴莲视频app of NSW)
  • Marianne Byrne (榴莲视频app of NSW)
  • Nicholas Lintzeris (榴莲视频app of Sydney/South Eastern Sydney Local Health District)
  • Robert Ali (榴莲视频app of Adelaide)
  • Suzanne Nielsen (Monash 榴莲视频app)
  • Jason Grebely (榴莲视频app of NSW)
  • Carla Treloar (榴莲视频app of NSW)
  • Kari Lancaster (榴莲视频app of NSW)
  • Adrian Dunlop (榴莲视频app of NSW)
  • Craig Rodgers (St Vincent鈥檚 Hospital Sydney)

Lead institution
榴莲视频app of New South Wales

Project description

The advent of novel extended release depot buprenorphine formulations has the potential to transform opioid agonist treatment in a variety of settings and benefit the lives of people living with opioid dependence. For example, the close level of monitoring conducted with current standard daily sublingual buprenorphine dosing may no longer be required. It is important to understand how this impacts on patient outcomes. In addition, making the shift to injectable treatments has important service- and system-level implications. The CoLAB project will evaluate patient outcomes following the implementation of monthly injection of depot buprenorphine for the treatment of opioid dependence, as well as develop and document the implementation in community-based treatment settings, with an emphasis on the feasibility and practical clinical, regulatory and supply issues in settings representative of Australian clinical practice.

Outcomes

With a focus on the patient experience and practical implementation of the treatment and its delivery, the research findings should be directly translatable and inform future clinical practice.

Funding

Industry grant (Indivior)